CPT Pharmacometrics & Systems Pharmacology · 2020 · 58 citations · 46 references
Life SciencesImmunologyPharmacologyCancer ImmunologyImmunotherapySystems PharmacologyCancer ImmunotherapyDisease ModelingImmune System ModelingQuantitative Systems PharmacologySystems Pharmacology In CancerSystems Pharmacology ModelingImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyImmuno-oncology ModelsImmunological ModelingImmunotherapy ModelingPredictive Biomarker ModelingPredictive BiomarkersQuantitative Pharmacology
Immunotherapy has shown great potential in the treatment of cancer; however, only a fraction of patients respond to treatment, and many experience autoimmune-related side effects. The pharmaceutical industry has relied on mathematical models to study the behavior of candidate drugs and more recently, complex, whole-body, quantitative systems pharmacology (QSP) models have become increasingly popular for discovery and development. QSP modeling has the potential to discover novel predictive biomarkers as well as test the efficacy of treatment plans and combination therapies through virtual clinical trials. In this work, we present a QSP modeling platform for immuno-oncology (IO) that incorporates detailed mechanisms for important immune interactions. This modular platform allows for the construction of QSP models of IO with varying degrees of complexity based on the research questions. Finally, we demonstrate the use of the platform through two example applications of immune checkpoint therapy.
46
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno et al. · Cell Reports · 2017 · 1.9K citations · Full text
Life Sciences, Immunology, Oncology +17
Maintenance of Peripheral Naive T Cells Is Sustained by Thymus Output in Mice but Not Humans
Ineke den Braber, Tendai Mugwagwa, Nienke Vrisekoop et al. · Immunity · 2012 · 573 citations · Full text